首页 > 最新文献

European Journal of Internal Medicine最新文献

英文 中文
GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity 用于治疗阻塞性睡眠呼吸暂停和肥胖症的 GLP-1 受体激动剂。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.10.027
Livia Romariz , Beatriz Araújo , Lucas M. Barbosa , Riddhi Jain , Carolina C. Porto Silva Janovsky , Obesity Study Group
{"title":"GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity","authors":"Livia Romariz , Beatriz Araújo , Lucas M. Barbosa , Riddhi Jain , Carolina C. Porto Silva Janovsky , Obesity Study Group","doi":"10.1016/j.ejim.2024.10.027","DOIUrl":"10.1016/j.ejim.2024.10.027","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 153-155"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Man with red eyes 红眼睛的男人。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.11.007
Naoya Ishibashi, Tomotaka Takanosu
{"title":"Man with red eyes","authors":"Naoya Ishibashi, Tomotaka Takanosu","doi":"10.1016/j.ejim.2024.11.007","DOIUrl":"10.1016/j.ejim.2024.11.007","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 127-128"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary metastases and bleeding in the anticoagulated oncology patient with thrombosis: is the risk solely influenced by the location of distant disease? 抗凝肿瘤合并血栓患者的肺转移和出血:风险仅受远处疾病位置的影响吗?
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.12.023
Manuel Sánchez Cánovas, Javier López Robles
{"title":"Pulmonary metastases and bleeding in the anticoagulated oncology patient with thrombosis: is the risk solely influenced by the location of distant disease?","authors":"Manuel Sánchez Cánovas, Javier López Robles","doi":"10.1016/j.ejim.2024.12.023","DOIUrl":"10.1016/j.ejim.2024.12.023","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 40-41"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primordial prevention of hypertension 高血压的基本预防。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.11.030
Claudio Ferri
{"title":"Primordial prevention of hypertension","authors":"Claudio Ferri","doi":"10.1016/j.ejim.2024.11.030","DOIUrl":"10.1016/j.ejim.2024.11.030","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 42-44"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining giant cell arteritis: From current practices to future paradigms 重新定义巨细胞动脉炎:从目前的实践到未来的范例。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.12.010
Alessandro Tomelleri , Nicola Farina , Lorenzo Dagna
{"title":"Redefining giant cell arteritis: From current practices to future paradigms","authors":"Alessandro Tomelleri , Nicola Farina , Lorenzo Dagna","doi":"10.1016/j.ejim.2024.12.010","DOIUrl":"10.1016/j.ejim.2024.12.010","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 37-39"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline 治疗住院高血糖患者:EFIM严格评价和调整指南。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.11.018
Oğuz Abdullah Uyaroğlu , Ieva Ruza , Jan Skrha , Dimitrios Patoulias , Sebastjan Bevc , Biljana Ivanovska Bojadjiev , Ricardo Gómez-Huelgas , Jörg Bojunga , Wiktoria Lesniak , Juana Carretero-Gómez , Julio Wacker , Luis M. Pérez-Belmonte , Dror Dicker , Tadej Petreski , Ignacio Marín-León

Background

Over the past decade, diabetes mellitus (DM) has emerged as a growing epidemic, with a direct link to an increased risk of hospitalization and a strong effect of glycemic control on clinical outcomes. The aim of this document was to critically appraise and adapt existing clinical practice guidelines (CPGs) to provide specific recommendations for the management of hyperglycemia in hospitalized adults with and without previously known DM, in an attempt to provide a practical tool to reduce the risk of major in-hospital complications.

Methods

The first step of the adaptation process was to identify unsolved clinical questions (PICOs) in hospitalized persons with hyperglycemia. This was followed by a critical appraisal of updated existing CPGs and the selection of recommendations that were most applicable to specific clinical situations.

Results

From the four updated high-quality evidence-based CPGs, 75 recommendations were selected, focusing on five common clinical scenarios in real-world practice: 1) glycemic targets; 2) persons with comorbidities; 3) elderly adults with low consciousness or dementia with irregular feeding or parenteral/enteral nutrition; 4) special hyperglycemic scenarios (stress hyperglycemia, corticosteroid treatment, fasting); and 5) glucose-lowering therapy at discharge. Of the 75 selected recommendations (59 strong and 16 weak), 37 were based on high-quality evidence, 8 on moderate-quality evidence, and 17 on low-quality evidence, while 13 were based on consensus (best practice statements). The recommendations apply to adults who are hospitalized or discharged from the hospital.

Conclusion

Using a systematic methodology, this guideline provides an updated and ease-to-use tool for the management of hospitalized adults with hyperglycemia.
背景:在过去的十年中,糖尿病(DM)已成为一种日益增长的流行病,与住院风险增加和血糖控制对临床结果的强烈影响有直接联系。本文的目的是对现有的临床实践指南(CPGs)进行批判性评估和调整,为有或没有糖尿病的住院成人的高血糖管理提供具体建议,试图提供一个实用的工具来降低院内主要并发症的风险。方法:适应过程的第一步是确定住院高血糖患者未解决的临床问题(PICOs)。随后,对更新的现有CPGs进行了批判性评估,并选择了最适用于特定临床情况的建议。结果:从4个更新的高质量循证cpg中,选择了75条建议,重点关注现实生活中常见的5种临床情景:1)血糖目标;2)有合并症者;3)老年人意识低下或痴呆,不规律喂养或肠外/肠内营养;4)特殊高血糖情况(应激性高血糖、皮质类固醇治疗、禁食);5)出院时降糖治疗。在选定的75项建议(59项强建议和16项弱建议)中,37项基于高质量证据,8项基于中等质量证据,17项基于低质量证据,而13项基于共识(最佳实践陈述)。这些建议适用于住院或出院的成年人。结论:采用系统的方法,本指南为住院成人高血糖的管理提供了一个更新和易于使用的工具。
{"title":"Treatment of hospitalized patient with hyperglycemia: An EFIM critically appraised and adapted guideline","authors":"Oğuz Abdullah Uyaroğlu ,&nbsp;Ieva Ruza ,&nbsp;Jan Skrha ,&nbsp;Dimitrios Patoulias ,&nbsp;Sebastjan Bevc ,&nbsp;Biljana Ivanovska Bojadjiev ,&nbsp;Ricardo Gómez-Huelgas ,&nbsp;Jörg Bojunga ,&nbsp;Wiktoria Lesniak ,&nbsp;Juana Carretero-Gómez ,&nbsp;Julio Wacker ,&nbsp;Luis M. Pérez-Belmonte ,&nbsp;Dror Dicker ,&nbsp;Tadej Petreski ,&nbsp;Ignacio Marín-León","doi":"10.1016/j.ejim.2024.11.018","DOIUrl":"10.1016/j.ejim.2024.11.018","url":null,"abstract":"<div><h3>Background</h3><div>Over the past decade, diabetes mellitus (DM) has emerged as a growing epidemic, with a direct link to an increased risk of hospitalization and a strong effect of glycemic control on clinical outcomes. The aim of this document was to critically appraise and adapt existing clinical practice guidelines (CPGs) to provide specific recommendations for the management of hyperglycemia in hospitalized adults with and without previously known DM, in an attempt to provide a practical tool to reduce the risk of major in-hospital complications.</div></div><div><h3>Methods</h3><div>The first step of the adaptation process was to identify unsolved clinical questions (PICOs) in hospitalized persons with hyperglycemia. This was followed by a critical appraisal of updated existing CPGs and the selection of recommendations that were most applicable to specific clinical situations.</div></div><div><h3>Results</h3><div>From the four updated high-quality evidence-based CPGs, 75 recommendations were selected, focusing on five common clinical scenarios in real-world practice: 1) glycemic targets; 2) persons with comorbidities; 3) elderly adults with low consciousness or dementia with irregular feeding or parenteral/enteral nutrition; 4) special hyperglycemic scenarios (stress hyperglycemia, corticosteroid treatment, fasting); and 5) glucose-lowering therapy at discharge. Of the 75 selected recommendations (59 strong and 16 weak), 37 were based on high-quality evidence, 8 on moderate-quality evidence, and 17 on low-quality evidence, while 13 were based on consensus (best practice statements). The recommendations apply to adults who are hospitalized or discharged from the hospital.</div></div><div><h3>Conclusion</h3><div>Using a systematic methodology, this guideline provides an updated and ease-to-use tool for the management of hospitalized adults with hyperglycemia.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 27-36"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FIB-4 score association with operative outcomes, truth or fibs? FIB-4 评分与手术结果的关系,真相还是谎言?
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.08.028
Brandon Stretton , Joshua Kovoor , Edmund Tse , Guy Maddern , Stephen Bacchi
{"title":"FIB-4 score association with operative outcomes, truth or fibs?","authors":"Brandon Stretton ,&nbsp;Joshua Kovoor ,&nbsp;Edmund Tse ,&nbsp;Guy Maddern ,&nbsp;Stephen Bacchi","doi":"10.1016/j.ejim.2024.08.028","DOIUrl":"10.1016/j.ejim.2024.08.028","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 139-141"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gliflozines use in heart failure patients. Focus on renal actions and overview of clinical experience 格列酮类药物在心力衰竭患者中的应用。关注肾脏作用并概述临床经验。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.09.009
Edoardo Gronda , Massimo Iacoviello , Arduino Arduini , Manuela Benvenuto , Domenico Gabrielli , Mario Bonomini , Luigi Tavazzi
Use of type 2 sodium-glucose cotransporter inhibitors (SGLT2i) gliflozines have first been applied to treatment of diabetic patients. In this setting, unexpected benefits on concomitant heart failure (HF) were seen in large trials. This clinical benefit was initially traced back to their natriuretic properties and as such they were also included in the therapeutic armamentarium of HF treatment. However, further insight into their mechanism of action has clarified their complex interaction with kidney function which better explains their prompt effectiveness in ameliorating HF outcome in the long-term, independent of left ventricular ejection fraction (LVEF) phenotype and concomitant presence of diabetes and/or chronic renal disease.
This mainly results from the ability of SGLT2i to counteract the HF-associated hyperactivity of the sympathetic system and neurohormonal activation by modifying the pattern of renal tubular sodium and glucose reabsorption which results in curbing the overall sodium reabsorption. Their action results in decreased kidney workload and related oxygen consumption thus indirectly reducing sympathetic activity.
The complex renal functional changes associated with HF and their modifications during SGLT2i administration will be reviewed.
2型钠-葡萄糖共转运抑制剂(SGLT2i)格列酮类药物首先用于治疗糖尿病患者。在这种情况下,在大型试验中出现了对并发心力衰竭(HF)的意想不到的疗效。这种临床益处最初被追溯到它们的利尿特性,因此它们也被纳入了心力衰竭的治疗范围。然而,对其作用机制的进一步深入研究阐明了它们与肾功能之间复杂的相互作用,从而更好地解释了它们在长期改善高血压预后方面的迅速有效性,而不受左心室射血分数(LVEF)表型和同时存在的糖尿病和/或慢性肾病的影响。这主要是因为 SGLT2i 能够通过改变肾小管钠和葡萄糖的重吸收模式,抑制钠的总体重吸收,从而抵消与高血压相关的交感神经系统亢进和神经激素激活。它们的作用导致肾脏工作量和相关耗氧量减少,从而间接降低了交感神经的活性。将对与高血压相关的复杂肾功能变化及其在服用 SGLT2i 期间的变化进行综述。
{"title":"Gliflozines use in heart failure patients. Focus on renal actions and overview of clinical experience","authors":"Edoardo Gronda ,&nbsp;Massimo Iacoviello ,&nbsp;Arduino Arduini ,&nbsp;Manuela Benvenuto ,&nbsp;Domenico Gabrielli ,&nbsp;Mario Bonomini ,&nbsp;Luigi Tavazzi","doi":"10.1016/j.ejim.2024.09.009","DOIUrl":"10.1016/j.ejim.2024.09.009","url":null,"abstract":"<div><div>Use of type 2 sodium-glucose cotransporter inhibitors (SGLT2i) gliflozines have first been applied to treatment of diabetic patients. In this setting, unexpected benefits on concomitant heart failure (HF) were seen in large trials. This clinical benefit was initially traced back to their natriuretic properties and as such they were also included in the therapeutic armamentarium of HF treatment. However, further insight into their mechanism of action has clarified their complex interaction with kidney function which better explains their prompt effectiveness in ameliorating HF outcome in the long-term, independent of left ventricular ejection fraction (LVEF) phenotype and concomitant presence of diabetes and/or chronic renal disease.</div><div>This mainly results from the ability of SGLT2i to counteract the HF-associated hyperactivity of the sympathetic system and neurohormonal activation by modifying the pattern of renal tubular sodium and glucose reabsorption which results in curbing the overall sodium reabsorption. Their action results in decreased kidney workload and related oxygen consumption thus indirectly reducing sympathetic activity.</div><div>The complex renal functional changes associated with HF and their modifications during SGLT2i administration will be reviewed.</div></div>","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 1-8"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring the risk of clinical adverse events (RISK ACE) by quantifying liver function: A patient-centric model 通过量化肝功能来测量临床不良事件风险(risk ACE):一个以患者为中心的模型。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.11.029
John Kittelson , Michael P. McRae , Gregory T. Everson
{"title":"Measuring the risk of clinical adverse events (RISK ACE) by quantifying liver function: A patient-centric model","authors":"John Kittelson ,&nbsp;Michael P. McRae ,&nbsp;Gregory T. Everson","doi":"10.1016/j.ejim.2024.11.029","DOIUrl":"10.1016/j.ejim.2024.11.029","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 160-163"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated to multiple chronic conditions in internal medicine patients 内科患者多种慢性病的相关因素。
IF 5.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.1016/j.ejim.2024.09.012
Marco Vincenzo Lenti , Carmine Frenna , Alice Silvia Brera , Catherine Klersy , Gino Roberto Corazza , SMAC Study group
{"title":"Factors associated to multiple chronic conditions in internal medicine patients","authors":"Marco Vincenzo Lenti ,&nbsp;Carmine Frenna ,&nbsp;Alice Silvia Brera ,&nbsp;Catherine Klersy ,&nbsp;Gino Roberto Corazza ,&nbsp;SMAC Study group","doi":"10.1016/j.ejim.2024.09.012","DOIUrl":"10.1016/j.ejim.2024.09.012","url":null,"abstract":"","PeriodicalId":50485,"journal":{"name":"European Journal of Internal Medicine","volume":"132 ","pages":"Pages 145-147"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1